Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 1,301–1,400 of 4,275
Chen, W., Altshuler, R. D., Daschner, P., Salvador-Morales, C., Germain, D. S., Guida, J., Prasanna, P. G. S., & Buchsbaum, J. C. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae163 · Cited by 69
SENEBLOC, a long non-coding RNA suppresses senescence via p53-dependent and independent mechanisms
Xu, C., Sang, B., Liu, G., Li, J., Zhang, X. D., Liu, L. X., Thorne, R. F., & Wu, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa063 · Cited by 55
“SA- -gal and SASP assays SA- -gal staining along with quantitation was performed as previously described (26).”
BackgroundInfluentialOhtani, N. (2019) · The Journal of Biochemistry · doi:10.1093/jb/mvz055 · Cited by 55
The struggle of a good friend getting old: cellular senescence in viral responses and therapy
Kohli, J., Veenstra, I., & Demaria, M. (2021) · The EMBO Reports · doi:10.15252/embr.202052243 · Cited by 52
Chemokines orchestrate tumor cells and the microenvironment to achieve metastatic heterogeneity
Saxena, S., & Singh, R. K. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09970-6 · Cited by 56
Detecting senescence: a new method for an old pigment
Salmonowicz, H., & Passos, J. F. (2017) · Aging Cell · doi:10.1111/acel.12580 · Cited by 52
Cellular senescence promotes progenitor cell expansion during axolotl limb regeneration
Yu, Q., Walters, H. E., Pasquini, G., Pal Singh, S., Lachnit, M., Oliveira, C. R., León-Periñán, D., Petzold, A., Kesavan, P., Subiran Adrados, C., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.09.009 · Cited by 52
Leontieva, O. V., Paszkiewicz, G. M., & Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100528 · Cited by 51
“The mTOR pathway stimulates protein synthesis and many cellular functions, including secretion of mitogens, insulin and cytokines, which remind the senescent phenotype [27-30].”
BackgroundTherapy-induced senescence as a component of tumor biology: Evidence from clinical cancer
Saleh, T., Bloukh, S., Hasan, M., & Shboul, S. A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188994 · Cited by 56
Senescent Cell Depletion Through Targeting BCL-Family Proteins and Mitochondria
Fan, Y., Cheng, J., Zeng, H., & Shao, L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.593630 · Cited by 51
“…et al., 2000); increased p16INK4a expression (Krishnamurthy et al., 2004; Ressler et al., 2006; Liu et al., 2009); DNA damage (Sedelnikova et al., 2004; d’Adda di Fagagna, 2008; Hewitt et al., 2012); and SASP-related factors (Coppé et al., 2010; Tchkonia et al., 2013; Hernandez-Segura et …”
Targeting organ-specific mitochondrial dysfunction to improve biological aging
Madreiter‐Sokolowski, C. T., Hiden, U., Krstić, J., Panzitt, K., Wagner, M., Enzinger, C., Khalil, M., Abdellatif, M., Malle, E., Madl, T., et al. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108710 · Cited by 59
Chen, J., Lazarenko, O. P., Blackburn, M. L., Rose, S., Frye, R. E., Badger, T. M., Andres, A., & Shankar, K. (2016) · Endocrinology · doi:10.1210/en.2016-1408 · Cited by 54
“Surprisingly, many of these SASP molecules were significantly up-regulated in EOCCs from HFD-induced obese dams compared with EOCCs from control dams (Figure 1E).”
BackgroundInfluentialNCI's provocative questions on cancer: some answers to ignite discussion
Blagosklonny, M. V. (2011) · Oncotarget · doi:10.18632/oncotarget.432 · Cited by 54
“First, senescent cells secrete pro-inflammatory factors [145-154].”
MicroRNAs, Long Non-Coding RNAs, and Circular RNAs in the Redox Control of Cell Senescence
Lettieri-Barbato, D., Aquilano, K., Punziano, C., Minopoli, G., & Faraonio, R. (2022) · Antioxidants · doi:10.3390/antiox11030480 · Cited by 51
Nelson, D. M., McBryan, T., Jeyapalan, J. C., Sedivy, J. M., & Adams, P. D. (2014) · AGE · doi:10.1007/s11357-014-9637-0 · Cited by 63
“…Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA phenotypes of senescence, a stable proliferation arrest and an altered secretory pathway, the senescenceassociated secretory phenotype (SASP; Krtolica et al. 2001; Coppe et al. 2008; Kuilman et al. 2008; Acosta et al. 2008).”
BackgroundSenescent Microvesicles: A Novel Advance in Molecular Mechanisms of Atherosclerotic Calcification
Alique, M., Ramírez-Carracedo, R., Bodega, G., Carracedo, J., & Ramírez, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072003 · Cited by 53
Beach, T. A., Johnston, C. J., Groves, A. M., Williams, J. P., & Finkelstein, J. N. (2017) · Experimental Lung Research · doi:10.1080/01902148.2017.1318975 · Cited by 55
“These include, but are not limited to, KC (Groα/Cxcl1), MCP-1 (Ccl2), and IL-6, [36, 37] all of which have been implicated in the onset of RIPF.”
BackgroundAging and Options to Halt Declining Immunity to Virus Infections
Palacios-Pedrero, M. Á., Osterhaus, A. D. M. E., Becker, T., Elbahesh, H., Rimmelzwaan, G. F., & Saletti, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681449 · Cited by 60
Reactive Oxygen Species Detection in Senescent Cells
Victorelli, S. G., & Passos, J. F. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8931-7_3 · Cited by 55
Heat Shock Alters Mesenchymal Stem Cell Identity and Induces Premature Senescence
Shimoni, C., Goldstein, M., Ribarski-Chorev, I., Schauten, I., Nir, D., Strauss, C., & Schlesinger, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.565970 · Cited by 50
Ding, J.-Y., Zhang, R., Li, H., Ji, Q., Cheng, X., Thorne, R. F., Hondermarck, H., Liu, X., & Shen, C. (2021) · Aging · doi:10.18632/aging.202850 · Cited by 52
“Senescence-associated secretory phenotype (SASP) assays Secreted IL-6 and IL-8 levels were measured using the human interleukin 6 (IL-6) and interleukin-8 (IL8/CXCL8) ELISA kits (MM-0049H1 and MM1558H1, Jiangsu Meimian Industrial Co., Ltd) according to the recommended protocols.”
BackgroundInfluentialCellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro
Prencipe, M., Fitzpatrick, P., Gorman, S., Mosetto, M., Klinger, R., Furlong, F. M., Harrison, M. J., O’Connor, D. P., Roninson, I. B., O’Sullivan, J. M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605419 · Cited by 53
“This phenomenon, recently described as the ‘senescenceassociated secretory phenotype’ (SASP) (Young and Narita, 2009), is gaining considerable research interest.”
BackgroundLoss of Arp2/3 induces an NF-κB–dependent, nonautonomous effect on chemotactic signaling
Wu, C., Haynes, E. M., Asokan, S. B., Simon, J. M., Sharpless, N. E., Baldwin, A. S., Davis, I. J., Johnson, G. L., & Bear, J. E. (2013) · The Journal of Cell Biology · doi:10.1083/jcb.201306032 · Cited by 53
“The nuclear factor B (NF-B) and p38 MAPK pathways have been shown to play important roles in regulating SASP (Coppé et al., 2008; Freund et al., 2011; Salminen et al., 2012; Tchkonia et al., 2013).”
InfluentialCell senescence as both a dynamic and a static phenotype
Young, A. R. J., Narita, M., & Narita, M. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-239-1_1 · Cited by 50
Roles of exosomal miRNA in vascular aging
Du, S., Ling, H., Guo, Z., Cao, Q., & Song, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105278 · Cited by 53
Macoska, J. A. (2011) · Differentiation · doi:10.1016/j.diff.2011.04.003 · Cited by 54
Lin, T.-Y., Cheng, Y.-C., Yang, H.-C., Lin, W.-C., Wang, C.-C., Lai, P.-L., & Shieh, S.-Y. (2011) · Oncogene · doi:10.1038/onc.2011.491 · Cited by 56
“This is believed to be mediated by the activation of the p16–RB pathway and of the ARF–p53 axis (Coppé et al., 2008).”
BackgroundA genomics approach identifies senescence‐specific gene expression regulation
Lackner, D. H., Hayashi, M. T., Cesare, A. J., & Karlseder, J. (2014) · Aging Cell · doi:10.1111/acel.12234 · Cited by 47
Ferrand, M., Kirsh, O., Griveau, A., Vindrieux, D., Martin, N., Defossez, P.-A., & Bernard, D. (2015) · Aging · doi:10.18632/aging.100845 · Cited by 50
Role of Inflammaging on the Reproductive Function and Pregnancy
Zavatta, A., Parisi, F., Mandò, C., Scaccabarozzi, C., Savasi, V. M., & Cetin, I. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08907-9 · Cited by 63
“However, excessive inflammation and its predisposing factors may accelerate the telomeres consumption and exacerbate SASP, with a consequent increase of oxidative stress damage and exacerbation of hypoxia, which turns to further deteriorate placental function and intrauterine environment [81, 82].”
BackgroundRole of Molecular Hydrogen in Ageing and Ageing‐Related Diseases
Fu, Z., Zhang, J., & Zhang, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2249749 · Cited by 57
“Cellular senescence is a stress response characterized by arrested cell proliferation and resistance to apoptosis [53].”
The senescence-associated secretory phenotype: Fueling a wound that never heals
Pulido, T., Velarde, M. C., & Alimirah, F. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111561 · Cited by 57
Senolytic Targeting of Bcl-2 Anti-Apoptotic Family Increases Cell Death in Irradiated Sarcoma Cells
Lafontaine, J., Cardin, G. B., Malaquin, N., Boisvert, J.-S., Rodier, F., & Wong, P. (2021) · Cancers · doi:10.3390/cancers13030386 · Cited by 54
“If so, those cells should also present a senescence-associated secretory phenotype (SASP) that is at least in part activated by DNA damage response signaling [24,25,27,28].”
BackgroundSelf-citationCr(VI) induces premature senescence through ROS-mediated p53 pathway in L-02 hepatocytes
Zhang, Y., Zhang, Y., Zhong, C., & Xiao, F. (2016) · Scientific Reports · doi:10.1038/srep34578 · Cited by 58
Molecular pathology of rare progeroid diseases
Rieckher, M., Garinis, G. A., & Schumacher, B. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.011 · Cited by 54
Yonas, E., Alwi, I., Pranata, R., Huang, I., Lim, M. A., Yamin, M., Nasution, S. A., Setiati, S., & Virani, S. S. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.11.011 · Cited by 50
Liu, P., Tang, Q., Chen, M., Chen, W., Lu, Y., Liu, Z., & He, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.589908 · Cited by 54
“Besides, SASP cytokines IL-6 and IL-8 and their signals exhibited detrimental paracrine effects of prolonged presence of senescent cells and caused tumor initiation, progression, and metastasis (63, 96).”
BackgroundSenescent cells in cancer therapy: why and how to remove them
Zhang, J., Zhang, D., & Yu, B. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.002 · Cited by 59
Shive, C. L., Freeman, M. L., Younes, S., Kowal, C. M., Canaday, D. H., Rodriguez, B. A., Lederman, M. M., & Anthony, D. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638010 · Cited by 55
“Senescent cells produce large volumes of inflammatory cytokines such as IL-6 and IL-8 and are described as having a senescence-associated secretory phenotype (SASP) (16).”
BackgroundCancer cell senescence: a new frontier in drug development
Cairney, C. J., Bilsland, A. E., Evans, T. R. J., Roffey, J., Bennett, D. C., Narita, M., Torrance, C. J., & Keith, W. N. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.019 · Cited by 50
Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer
Kallenbach, J., Roozbahani, G. A., Horestani, M. H., & Baniahmad, A. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00941-0 · Cited by 58
“This drug induces SASP factors and increases the mRNA expression of the senescence markers p16INK4a and p21WAF1/CIP1 in three different prostate epithelial cancer cell lines BPH-1, RWPE-1, and PC3 and prostatectomy samples from PCa patients [32].”
BackgroundAdvances in the study of the glymphatic system and aging
Xiong, Y., Yu, Q., Zhi, H., Peng, H., Xie, M., Li, R., Li, K., Ma, Y., & Sun, P. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14803 · Cited by 59
IFN-γ and TNF Induce Senescence and a Distinct Senescence-Associated Secretory Phenotype in Melanoma
Homann, L., Rentschler, M., Brenner, E., Böhm, K., Röcken, M., & Wieder, T. (2022) · Cells · doi:10.3390/cells11091514 · Cited by 65
“Another feature of senescent cells is the release of numerous molecules into their surrounding environment, which are collectively known as the senescence-associated secretory phenotype (SASP) [35,36].”
BackgroundTargeting Cell Senescence for the Treatment of Age-Related Bone Loss
Pignolo, R. J., Samsonraj, R. M., Law, S. F., Wang, H., & Chandra, A. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00504-2 · Cited by 54
Progeria, rapamycin and normal aging: recent breakthrough
Blagosklonny, M. V. (2011) · Aging · doi:10.18632/aging.100352 · Cited by 50
“In cell culture, senescence is characterized by large flat cell morphology (hypertrophy), beta-Gal staining, hyper-secretory phenotype, activated DNA-damage response (even in the absence of DNA damage), resistance to signals (such as insulin), elevated cyclins with inappropriate drive into S-phase, and loss of prolife…”
BackgroundBoquoi, A., Arora, S., Chen, T., Litwin, S., Koh, J., & Enders, G. H. (2015) · Aging Cell · doi:10.1111/acel.12279 · Cited by 49
“S8, Supporting information); and the microarray analysis showed no induction of secretory proteins that are often induced at the mRNA level in senescence in vitro (Coppe et al., 2008) (Fig.”
BackgroundThe Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications
Santi, A. L., Napolitano, F., Montuori, N., & Ragno, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084111 · Cited by 52
“Interestingly, suPAR is secreted by senescent cells as part of the SASP [88] and, recently, uPAR expression on the surface of senescent cells in vitro and in vivo has been reported and even targeted by senolytic CAR T cells [84].”
BackgroundNF90 coordinately represses the senescence-associated secretory phenotype
Tominaga-Yamanaka, K., Abdelmohsen, K., Martindale, J. L., Yang, X., Taub, D. D., & Gorospe, M. (2012) · Aging · doi:10.18632/aging.100497 · Cited by 49
“1C,D), supporting the view that besides higher secretion, SASP factor biosynthesis was also upregulated in senescent cells [4].”
BackgroundMethodShen, M., Luo, Y., Niu, Y., Chen, L., Yuan, X., Goltzman, D., Chen, N., & Miao, D. (2013) · Bone · doi:10.1016/j.bone.2013.04.015 · Cited by 53
Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing
Mongiardi, M. P., Pellegrini, M., Pallini, R., Levi, A., & Falchetti, M. L. (2021) · Cancers · doi:10.3390/cancers13030484 · Cited by 53
Biphasic Modeling of Mitochondrial Metabolism Dysregulation during Aging
Baker, D. J., & Peleg, S. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.06.005 · Cited by 49
Targeting cellular senescence as a novel treatment for osteoarthritis
Astrike‐Davis, E. M., Coryell, P., & Loeser, R. F. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102213 · Cited by 53
Serum proton NMR metabolomics analysis of human lung cancer following microwave ablation
Hu, J.-M., & Sun, H. (2018) · Radiation Oncology · doi:10.1186/s13014-018-0982-5 · Cited by 48
“Some oncogene and tumor suppressor gene were found, such as the tumor suppressor gene of p53 [14] SIRT3 [15] and SIRT6 [16], and oncogene of Ras [17] PI3K [18], AKT [19] and c-Myc [20].”
BackgroundBacterial genotoxins induce T cell senescence
Mathiasen, S. L., Gall-Mas, L., Pateras, I. S., Theodorou, S. D. P., Namini, M. R. J., Hansen, M., Martin, O. C. B., Vadivel, C. K., Ntostoglou, K., Butter, D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109220 · Cited by 51
“An important feature distinguishing senescent cells from nonsenescent cell-cycle-arrested cells is that they typically acquire a senescence-associated secretory phenotype (SASP)—a phenomenon characterized by highly increased expression of a wide array of secreted proteins including inflammatory mediators (Coppé et al.…”
BackgroundDreij, K., Rhrissorrakrai, K., Gunsalus, K. C., Geacintov, N. E., & Scicchitano, D. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq073 · Cited by 60
Marcoux, S., Le, O. N., Langlois-Pelletier, C., Laverdière, C., Hatami, A., Robaey, P., & Beauséjour, C. M. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-252 · Cited by 49
“Yet, IL-6 mRNA levels (a senescence-associated secretory phenotype marker) [21] was not increased in all but one scalp biopsy (data not shown).”
Role of lncRNAs in Cellular Aging
Degirmenci, U., & Sun, L. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00151 · Cited by 54
“Nat Struct Mol Biol (2012) 19(9):948–56.”
The nuclear receptor and clock gene REV-ERBα regulates cigarette smoke-induced lung inflammation
Sundar, I. K., Rashid, K., Sellix, M. T., & Rahman, I. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.157 · Cited by 52
“Persistent DNA damage results in SIPS and senescence-associated secretory phenotype (SASP) by forming senescence-associated heterochromatin foci [26, 27].”
BackgroundBhattacharya, S., Das, A. K., Datta, S., Ganguli, A., & Chakrabarti, G. (2016) · Tumor Biology · doi:10.1007/s13277-016-4972-7 · Cited by 56
Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes
Fordyce, C. A., Patten, K. T., Fessenden, T. B., DeFilippis, R., Hwang, E. S., Zhao, J., & Tlsty, T. D. (2012) · Breast Cancer Research · doi:10.1186/bcr3368 · Cited by 50
“It has also been argued that factors secreted by senescent cells elicit deleterious cell nonautonomous effects that alter the tissue microenvironment [44].”
BackgroundDNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity
van Jaarsveld, M. T. M., Wouters, M. D., Boersma, A. W. M., Smid, M., van IJcken, W. F. J., Mathijssen, R. H. J., Hoeijmakers, J. H. J., Martens, J. W. M., Laere, S. V., Wiemer, E. A. C., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.011 · Cited by 50
“In contrast to cisplatin, a high dose of IR did not lead to apoptosis but to cellular senescence, which does not affect cellular viability as measured by the MTT assay (Supplemental Figure 3C) (Bunnak et al., 1994; Coppe et al., 2008; Sabin and Anderson, 2011).”
BackgroundMethodDiverse Roles of Cellular Senescence in Skeletal Muscle Inflammation, Regeneration, and Therapeutics
Saito, Y., & Chikenji, T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739510 · Cited by 56
Anti-ageing effects of ubiquinone and ubiquinol in a senescence model of human dermal fibroblasts
Marcheggiani, F., Kordes, S., Cirilli, I., Orlando, P., Silvestri, S., Vogelsang, A., Möller, N., Blatt, T., Weise, J. M., Damiani, E., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.01.032 · Cited by 48
Reed-Sternberg cells in Hodgkin’s lymphoma present features of cellular senescence
Gopas, J., Stern, E., Zurgil, U., Ozer, J., Ben-Ari, A., Shubinsky, G., Braiman, A., Sinay, R., Ezratty, J., Dronov, V., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.185 · Cited by 58
Campisi, J. (2014) · Nature · doi:10.1038/nature12844 · Cited by 48
Self-citationWideł, M., Lalik, A., Krzywon, A., Poleszczuk, J., Fujarewicz, K., & Rzeszowska‐Wolny, J. (2015) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2015.06.003 · Cited by 53
Despars, G., Carbonneau, C. L., Bardeau, P., Coutu, D. L., & Beausejour, C. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073206 · Cited by 52
Synergism of BCL-2 family inhibitors facilitates selective elimination of senescent cells
Rysanek, D., Vašicová, P., Kolla, J. N., Sedlák, D., Anděra, L., Bártek, J., & Hodný, Z. (2022) · Aging · doi:10.18632/aging.204207 · Cited by 50
Minireview: Physiological and Pathological Actions of RAS in the Ovary
Fan, H., & Richards, J. S. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0251 · Cited by 54
“A major difference is that RAS-induced senescent epithelial cells continue to produce copious amounts of cytokines (80) and continue to express the KRAS gene, whereas terminally differentiated granulosa cells do not.”
BackgroundImmunosuppressants in cancer prevention and therapy
Blagosklonny, M. V. (2013) · OncoImmunology · doi:10.4161/onci.26961 · Cited by 48
Malvaso, A., Gatti, A., Negro, G., Calatozzolo, C., Medici, V., & Poloni, T. E. (2023) · Cells · doi:10.3390/cells12242824 · Cited by 66
“In recent years, as suggested by several studies, this term has also been interpreted to mean the age-related shift in the secretory profile (senescence-associated secretory phenotype—SASP) [37–39].”
BackgroundSenescence and Apoptosis: Architects of Mammalian Development
Wanner, E., Thoppil, H., & Riabowol, K. T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.620089 · Cited by 59
The Clearance Effect of Tetrahedral DNA Nanostructures on Senescent Human Dermal Fibroblasts
Mao, C., Pan, W., Shao, X., Ma, W., Zhang, Y., Zhan, Y., Gao, Y., & Lin, Y. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b20530 · Cited by 49
Telomere Length Influences Cancer Cell Differentiation In Vivo
Hirashima, K., Migita, T., Sato, S., Muramatsu, Y., Ishikawa, Y., & Seimiya, H. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00136-13 · Cited by 50
“S7B in the supplemental material), indicating that short telomeres in PC-3 cells did not elicit the SASP in vivo.”
BackgroundInfluentialLewińska, A., Radoń, A., Gil, K., Błoniarz, D., Ciuraszkiewicz, A., Kubacki, J., Kądziołka-Gaweł, M., Łukowiec, D., Gębara, P., Krogul-Sobczak, A., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c17418 · Cited by 51
Muñoz-Galván, S., Lucena-Cacace, A., Pérez, M., Otero-Albiol, D., Gómez-Cambronero, J., & Carnero, A. (2018) · Oncogene · doi:10.1038/s41388-018-0527-2 · Cited by 50
MicroRNAs as a novel cellular senescence regulator
Liu, F., Wen, T., & Liu, L. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.06.001 · Cited by 56
Chen, H., Hu, X., Yang, R., Wu, G., Tan, Q., Goltzman, D., & Miao, D. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.48169 · Cited by 54
“arrest, and senescent cells acquire a senescenceassociated secretory phenotype (SASP) [42].”
BackgroundInfluentialMultifaceted functions of the forkhead box transcription factors FoxO1 and FoxO3 in skin
Tsitsipatis, D., Klotz, L., & Steinbrenner, H. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.02.027 · Cited by 47
“Senescent cells have lost their proliferative capacity but remain metabolically active and can even secrete soluble factors that may influence neighboring cells [35].”
BackgroundRevisiting ovarian cancer microenvironment: a friend or a foe?
Zhang, B., Chen, F., Xu, Q., Han, L., Xu, J., Gao, L., Sun, X., Li, Y., Li, Y., Qian, M., et al. (2017) · Protein & Cell · doi:10.1007/s13238-017-0466-7 · Cited by 51
“Upon treatments by anticancer agents, stromal expression of VEGF and other angiogeneic factors including angiopoietin 1 (ANGPT1) and angiopoietin-like 4 (ANGPTL4) is increased, functionally stimulating vasculature development within the drug-remodeled TME (Coppe et al., 2008; Sun et al., 2012).”
BackgroundSelf-citationZhao, D., Gao, Y., Su, Y., Zhou, Y., Yang, T., Yang, L., Wang, Y., Sun, Y., Chen, L., Zhang, F., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106590 · Cited by 54
Self-citationMaternal obesity impairs skeletal development in adult offspring
Chen, J., Lazarenko, O. P., Zhao, H., Alund, A. W., & Shankar, K. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0244 · Cited by 45
Janelle, V., & Delisle, J. (2021) · Cancers · doi:10.3390/cancers13040598 · Cited by 55
Bobak, C. A., Abhimanyu, A., Natarajan, H., Gandhi, T., Grimm, S. L., Nishiguchi, T., Koster, K. J., Longlax, S. C., Dlamini, Q., Kahari, J., et al. (2022) · Aging · doi:10.18632/aging.203936 · Cited by 53
“The serum was evaluated by using nine soluble markers of senescence associated secretory phenotype as defined previously [53, 54], including IL15 (TB = 40, HC = 39), TNFA (TB = 152, HC = 111), IL1B (TB = 152, HC = 111), CXCL10 ( TB = 70, HC = 49), IL6 (TB = 70, HC = 49), CXCL9 (TB = 152, HC = 111), IL7 (TB = 112, HC =…”
Immune Alterations with Aging: Mechanisms and Intervention Strategies
Yu, W., Yu, Y., Sun, S., Lu, C., Zhai, J., Lei, Y., Bai, F., Wang, R., & Chen, J. (2024) · Nutrients · doi:10.3390/nu16223830 · Cited by 61
“In 2008, the SASP, also known as the senescence-messaging secretome, was independently characterized by various laboratories as primarily consisting of pro-inflammatory and growth-stimulating proteins [56,57].”
Pathobiology of biliary epithelia
Cheung, A., Pisarello, M. J. L., & LaRusso, N. F. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.06.024 · Cited by 50
Mannino, M., Gomez-Roman, N., Hochegger, H., & Chalmers, A. J. (2014) · Stem Cell Research · doi:10.1016/j.scr.2014.05.001 · Cited by 52
Liu, Y., Pan, J., Pan, X., Wu, L., Bian, J., Lin, Z., Xue, M., Su, T., Lai, S., Chen, F., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12577 · Cited by 52
Rusanova, I., Fernández‐Martínez, J., Fernández‐Ortiz, M., Aranda‐Martínez, P., Escames, G., García‐García, F. J., Rodríguez‐Mañas, L., & Acuña-Castroviejo, D. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110637 · Cited by 47
Potential Role of Cellular Senescence in Asthma
Wang, Z.-N., Su, R., Yang, B.-Y., Yang, K., Yang, L., Yan, Y., & Chen, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00059 · Cited by 51
Barajas-Gómez, B. A., Rosas‐Carrasco, Ó., Morales-Rosales, S. L., Pedraza-Vázquez, G., González‐Puertos, V. Y., Juárez‐Cedillo, T., García, J. A., López‐Díazguerrero, N. E., Damián‐Matsumura, P., Königsberg, M., et al. (2016) · Cytokine · doi:10.1016/j.cyto.2016.12.001 · Cited by 53
Crosstalk between gut microbiota and cellular senescence: a vicious cycle leading to aging gut
Kawamoto, S., & Hara, E. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.12.004 · Cited by 49
The role of MIF in chronic lung diseases: looking beyond inflammation
Florez-Sampedro, L., Soto-Gamez, A., Poelarends, G. J., & Melgert, B. N. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00521.2019 · Cited by 47
“Considering that MIF has been described as a protein secreted by senescent cells, it is possible that MIF also contributes to the profibrotic effect of the senescent cell secretome (15).”
BackgroundAging, Senescence, and Dementia
Behfar, Q., Zuniga, A. R., & Adami, P. V. M. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.42 · Cited by 58
“JPAD - Volume 9, Number 3, 2022 Even though the majority of SASP factors are up-regulated at the mRNA level, partially due to increased nuclear factor kappa B (NF-κB) (32, 33), there is also evidence of epigenetic regulation.”
BackgroundSenescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner
Warde, K. M., Smith, L., Liu, L., Stubben, C., Lohman, B. K., Willett, P. W., Ammer, J. L., Castaneda-Hernandez, G., Imodoye, S. O., Zhang, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00420-2 · Cited by 52
Molecular mechanisms and cardiovascular implications of cancer therapy-induced senescence
Abdelgawad, I. Y., Sadak, K. T., Lone, D. W., Dabour, M. S., Niedernhofer, L. J., & Zordoky, B. N. M. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107751 · Cited by 50
Senescence and the Pro-tumorigenic Stroma
Alspach, E., Fu, Y., & Stewart, S. A. (2013) · Critical Reviews in Oncogenesis · doi:10.1615/critrevoncog.2014010630 · Cited by 47
McCarthy, C. G., Wenceslau, C. F., Webb, R. C., & Joe, B. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz052 · Cited by 50
Pleiotropic actions of estrogen: a mitochondrial matter
Velarde, M. C. (2013) · Physiological Genomics · doi:10.1152/physiolgenomics.00155.2012 · Cited by 47
“Senescent cells distinctly upregulate the expression of several inflammatory cytokines (14, 15).”
BackgroundCellular Senescence and Periodontitis: Mechanisms and Therapeutics
Chen, S., Zhou, D., Liu, O., Chen, H., Wang, Y., & Zhou, Y. (2022) · Biology · doi:10.3390/biology11101419 · Cited by 65
“Arrested cell proliferation, resistance to apoptosis and a complex SASP are three hallmarks of senescent cells [29].”
Background
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.